Clarametyx Biosciences Achieves Milestones in Investment, Clinical Trials, and Industry Recognition
Clarametyx Biosciences marked a year of impressive growth in 2024. The company’s progress highlights the potential of transformative therapies in the fight against antibiotic-resistant infectious diseases.
Clarametyx Biosciences, a clinical-stage biotechnology company, launched 2024 with a bell-ringing $33 million Series A financing round with new investors, prior investors—including Rev1 Ventures—and backing by the Cystic Fibrosis Foundation. The focus of the round is to accelerate clinical trials across Clarametyx’s pipeline of immune-enabling therapeutics, including those combating infections in people with cystic fibrosis (CF).
Building on this momentum, Clarametyx successfully completed Phase 1b safety trials for its lead antibody therapy, CMTX-101, and then announced a Phase 2a study enrolling 41 adults with cystic fibrosis. The company concluded 2024 with industry accolades as “Infectious Disease Innovation of the Year” at the 2024 BioTech Breakthrough Awards.
“We recognize that recurrent infections are a significant challenge for people living with cystic fibrosis and their families, and believe that a truly novel approach to help the patient’s immune system and today’s antibiotics more effectively clear these infections can not only alleviate the burden on these patients but also support greater antibiotic stewardship and potentially reduce resistance issues,”said David Richards, Chief Executive Officer. (Read more)
Founded in 2020 with licensed technology from Nationwide Children’s Hospital (NCH) and The Ohio State University (OSU) Clarametyx Biosciences, is pioneering treatments that break down biofilm—the protective barrier that makes bacterial infections resistant to antibiotics . Rev1 Ventures, which co-led Clarametyx’s initial seed financing round back in 2020, continues to play an instrumental role in the company’s growth and recent funding efforts.
“Along with breakthrough technology and excellent leadership, capital attraction is essential for success, said Tom Walker, CEO Rev1 Ventures. “Rev1 has been with Clarametyx since the beginning, providing not just funding, but venture services. The multi-directional collaborations like Clarametyx that Rev1 shares with NHC and OSU demonstrate the immense potential for life sciences in Central Ohio.”
Through its strategic partnerships and early-stage support can capital for life science technologies, Rev1 Ventures has helped life sciences companies raise over $830 million in co-investment and follow-on funding, leading to more than $530 million in successful exits. The continued success of Clarametyx underscores the importance of fostering innovative companies with the potential to reshape industries.
“Clarametyx is making important strides, and we are already seeing the impact of fueling innovations like this in the market,” said Tim Robinson, Chief Executive Officer at Nationwide Children’s Hospital. “By bringing together research institutions, investors, and strategic advisors, we’re elevating Central Ohio’s position in the industry and helping to bring more life-saving solutions to the world.” (Read more)
By developing therapies that can clear infections without relying on traditional antibiotics, Clarametyx is paving the way for a new era in infection treatment. By fueling breakthrough technologies and ensuring they reach the market, Rev1 and its research partners are not just supporting businesses—they’re creating lasting change in healthcare and beyond.
#
